Chimeric Therapeutics LimitedASX: CHM

Appointment of Financial Adviser for Strategic Review

· Issued by Chimeric Therapeutics Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Chimeric Therapeutics Limited has appointed Hawkesbury Partners as its Independent Financial Adviser to conduct a strategic review aimed at maximizing shareholder value. The Board is exploring various strategic and funding options, including partnerships and asset sales, to enhance the company's market position. Hawkesbury Partners will evaluate opportunities to realize value from Chimeric's clinical programs and infrastructure investments. The company emphasizes that there is no guarantee of any transactions resulting from this review process.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Chimeric Therapeutics Limited on 6ix

Earlier from Chimeric Therapeutics

Later from Chimeric Therapeutics

All Chimeric Therapeutics news releases